Development and characterization of a camelid single‐domain antibody directed to human CD22 biomarker

Abstract CD22 is a B‐cell‐specific trans‐membrane glycoprotein, which is found on the surface of the most B cells and modulates their function, survival, and apoptosis. Recently, targeting this cell surface biomarker in B‐cell malignancies and disorders has attracted a lot of attention. The variable domain of camelid single‐chain antibodies (VHH, nanobody) is a form of antibodies with novel properties including small size (15–17 kDa), thermal and chemical stability, high affinity and homology to human antibody sequences. In this study, a novel anti‐CD22‐specific VHH (Nb) has been developed and characterized by the screening of an immunized phage display library and its binding to CD22 + B cells is evaluated. Produced anti‐CD22 VHH had a single protein band about 17 kDa of molecular size in Western blotting and its binding affinity was approximately 9 × 10 −9 M. Also, this product had high specificity and it was able to recognize the natural CD22 antigen in CD22+ cell lysate as well as on the cell surface (93%). This anti‐CD22 VHH with both high affinity and specificity recognizes CD22 antigen well and can be used in diagnosis and treatment of B cell disorders and malignancies.